Interchange Capital Partners LLC Sells 464 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Interchange Capital Partners LLC cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 30.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,036 shares of the pharmaceutical company’s stock after selling 464 shares during the quarter. Interchange Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Eagle Asset Management Inc. raised its holdings in shares of Vertex Pharmaceuticals by 21.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 8,119 shares of the pharmaceutical company’s stock valued at $4,195,000 after buying an additional 1,440 shares in the last quarter. Nicolet Advisory Services LLC raised its stake in shares of Vertex Pharmaceuticals by 4.6% during the third quarter. Nicolet Advisory Services LLC now owns 641 shares of the pharmaceutical company’s stock worth $291,000 after acquiring an additional 28 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Vertex Pharmaceuticals by 21.9% in the 3rd quarter. Larson Financial Group LLC now owns 417 shares of the pharmaceutical company’s stock worth $194,000 after acquiring an additional 75 shares during the last quarter. Centaurus Financial Inc. boosted its stake in shares of Vertex Pharmaceuticals by 18.4% in the 3rd quarter. Centaurus Financial Inc. now owns 1,858 shares of the pharmaceutical company’s stock valued at $864,000 after purchasing an additional 289 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in shares of Vertex Pharmaceuticals by 133.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,272 shares of the pharmaceutical company’s stock valued at $592,000 after purchasing an additional 728 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company’s stock, valued at $30,805,286.70. This represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $511.74 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a 50 day moving average price of $469.86 and a 200-day moving average price of $462.79. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The firm has a market capitalization of $131.41 billion, a price-to-earnings ratio of -232.61, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the subject of several analyst reports. Scotiabank upped their price target on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 11th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target on the stock. in a research report on Thursday, January 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Finally, Bank of America lowered their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.